Glutathione peroxidase and malondialdehyde in children with chronic hepatitis C

Mohammed Ahmed Khedr1, Hanaa Ahmed El-Araby1, Hatem Abdel-Sattar Konsowa1

  • 1Department of Pediatric Hepatology, Gastroenterology and Nutrition, National Liver Institute, Menoufia University, Shebin El-koom, Menoufia, Egypt.

Insights

Children with chronic hepatitis C show increased oxidative stress markers, indicated by lower glutathione peroxidase (GPX) and higher malondialdehyde (MDA) levels. Treatment response correlates with the normalization of these oxidative stress indicators.

Area of Science:

  • Hepatology
  • Biochemistry
  • Pediatrics

Background:

  • Chronic hepatitis C (CHC) in children is a significant health concern.
  • Oxidative stress plays a role in the pathogenesis of viral hepatitis.
  • Understanding oxidative stress markers can aid in assessing disease severity and treatment outcomes.

Purpose of the Study:

  • To evaluate oxidative stress markers, specifically glutathione peroxidase (GPX) and malondialdehyde (MDA), in children with CHC.
  • To investigate the relationship between these markers and treatment response in pediatric HCV patients.

Main Methods:

  • The study included 50 treatment-naïve children with CHC, 25 responders, 25 non-responders, and 25 healthy controls.
  • Glutathione peroxidase (GPX) activity and malondialdehyde (MDA) levels were measured using enzyme-linked immunosorbent assay (ELISA).

Main Results:

  • Naïve CHC patients exhibited significantly lower erythrocyte GPX activity and higher plasma MDA levels compared to healthy controls.
  • Responder patients showed higher GPX and lower MDA levels than non-responders, indicating a reversal of oxidative stress.
  • Non-responder patients had significantly lower GPX and higher MDA levels compared to healthy controls and responders.

Conclusions:

  • Pretreatment low GPX and high MDA levels may serve as indicators of oxidative stress in pediatric CHC.
  • The normalization of GPX and MDA levels post-treatment suggests a link between oxidative stress and HCV pathogenesis.
  • These markers could potentially predict treatment response and disease progression in children with CHC.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
267
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
886
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
222
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
267
Chronic Pharyngitis01:23

Chronic Pharyngitis

Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
11.7K